French medtech UroMems lands $60M from Ajax Health to tackle urinary incontinence
What's the deal? UroMems, a French medical device company developing an artificial urinary sphincter, has raised $60 million in a strategic investment from US-based Ajax Health Fund I. The funding will support the company's efforts to bring its smart implantable device through clinical trials and toward regulatory approval.
UroMems is building a next-generation artificial urinary sphincter — a condition that affects millions of people worldwide but has seen little innovation in decades. Ajax Health, which focuses on medtech investments, led the round.
Why now? The urinary incontinence device market has been ripe for disruption. The current standard of care — a mechanical artificial sphincter — has remained largely unchanged for over 40 years. UroMems aims to replace it with a sensor-driven, automated implant that adapts to patient activity in real time.
The company likely needed significant capital to fund its pivotal clinical trials and navigate the lengthy regulatory pathway in both Europe and the US.
What could go wrong? Medtech companies face notoriously long timelines between clinical development and commercialisation. Regulatory hurdles, manufacturing complexity, and reimbursement challenges could all slow UroMems' path to market. The company also operates in a niche segment, which could limit its addressable market despite clear unmet clinical need.
The signal: This deal reflects growing investor appetite for medtech companies tackling underserved conditions with smart, sensor-based implantable devices. Ajax Health's involvement — a fund specifically built to back medical technology — suggests that specialised investors see significant upside in modernising legacy surgical devices with digital and AI-enabled approaches.
The $60 million raise also underscores a broader trend: US healthcare-focused funds increasingly looking to European medtech startups for innovation, then backing them through the expensive process of cracking the American market.
Read more: prnewswire.com
